These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

383 related items for PubMed ID: 12837047

  • 21. Safety and toxicological evaluation of undenatured type II collagen.
    Marone PA, Lau FC, Gupta RC, Bagchi M, Bagchi D.
    Toxicol Mech Methods; 2010 May; 20(4):175-89. PubMed ID: 20170336
    [Abstract] [Full Text] [Related]

  • 22. Humoral immune response to citrullinated collagen type II determinants in early rheumatoid arthritis.
    Burkhardt H, Sehnert B, Bockermann R, Engström A, Kalden JR, Holmdahl R.
    Eur J Immunol; 2005 May; 35(5):1643-52. PubMed ID: 15832289
    [Abstract] [Full Text] [Related]

  • 23. [Therapy with oral type II collagen as a new possibility of selective immunosuppression in therapy of rheumatoid arthritis].
    Sieper J, Mitchison AN.
    Z Rheumatol; 1994 May; 53(2):53-8. PubMed ID: 8023585
    [Abstract] [Full Text] [Related]

  • 24. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis.
    Chopin F, Garnero P, le Henanff A, Debiais F, Daragon A, Roux C, Sany J, Wendling D, Zarnitsky C, Ravaud P, Thomas T.
    Ann Rheum Dis; 2008 Mar; 67(3):353-7. PubMed ID: 17644538
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Oral administration of type-II collagen suppresses IL-17-associated RANKL expression of CD4+ T cells in collagen-induced arthritis.
    Ju JH, Cho ML, Jhun JY, Park MJ, Oh HJ, Min SY, Cho YG, Hwang SY, Kwok SK, Seo SH, Yoon CH, Park SH, Kim HY.
    Immunol Lett; 2008 Apr 15; 117(1):16-25. PubMed ID: 18242716
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Prevention of pristane-induced arthritis by the oral administration of type II collagen.
    Thompson SJ, Thompson HS, Harper N, Day MJ, Coad AJ, Elson CJ, Staines NA.
    Immunology; 1993 May 15; 79(1):152-7. PubMed ID: 8509136
    [Abstract] [Full Text] [Related]

  • 38. [Points of undenatured type II collagen application in musculoskeletal pain syndromes treatment].
    Shavlovskaya OA, Gromova OA, Torshin IY.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2022 May 15; 122(11):40-45. PubMed ID: 36440775
    [Abstract] [Full Text] [Related]

  • 39. Oral desensitization in the treatment of human immune diseases.
    Vischer TL.
    Z Rheumatol; 1995 May 15; 54(3):155-7. PubMed ID: 7544938
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.